课题基金 / 基金详情

Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING): a pragmatic, randomised, parallel group, open, phase 3, international superiority trial

Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING): a pragmatic, randomised, parallel group, open, phase 3, international superiority trial
脑出血后抗血小板二级预防国际随机试验 (ASPIRING)：一项务实、随机、平行组、开放、3 期国际优越性试验
批准号：
463680
负责人：
Shoamanesh Ashkan
金额：
$70.5万
依托单位：
Population Health Research Institute (Hamilton, ON)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2028-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=463680&lang=en
关键词：
Antiplatelet Treatment Antithrombotic Treatment Hemorrhagic Stroke Intracerebral Hemorrhage Major Cardiovascular Events Randomized Trial Stroke

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
Asping旨在改善因脑出血而幸存下来的中风患者的护理，这种中风被称为出血性中风。当虚弱的血管破裂并导致大脑出血时，就会发生出血性中风。出血性中风患者
英文摘要
ASPIRING aims to improve the care of patients who survive stroke due to bleeding in the brain, known as "hemorrhagic stroke". Hemorrhagic strokes happen when weakened blood vessels rupture and cause bleeding in the brain. Patients with hemorrhagic stroke
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金